Andrei POPESCU and Rodica Maricela ANGHEL

ABSTRACT

Objective: To put in perspective recent advances in the treatment of malignant melanoma with novel tyrosine-kinase inhibitors.
Methods: We reviewed the largest trials that support the treatment with tyrosine-kinase inhibitors (TKIs) in cutaneous malignant melanoma, the base of the current guideline recommendations.
Conclusions: Mitogen-activated protein-kinase (MAPK) pathway inhibition via modern TKIs is a major breakthrough in the treatment of melanoma, with a very high benefit for patients with disease harboring BRAF-gene mutations, in terms of rates of response and survival.
Keywords: malignant melanoma, tyrosine-kinase inhibitors, BRAF mutation.

Full text | PDF